Practical guide to the use of chemotherapy in castration resistant prostate cancer

Canadian Journal of Urology

Volumn 21, Issue , 2014, Pages 77-83

  Petrylak, Daniel P ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Cabazitaxel; Castration resistant prostate cancer; Chemotherapy; Docetaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CABAZITAXEL; DOCETAXEL; PREDNISONE; TAXOID;

DRUG COMBINATION; DRUG THERAPY; HUMAN; MALE; MORTALITY; PRACTICE GUIDELINE; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

ANTINEOPLASTIC AGENTS; DRUG THERAPY; DRUG THERAPY, COMBINATION; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84927566625     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin 2014;64(1):9-29.
2. Crawford ED, Goodman P, Blumenstein B. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo. Semin Urol 1990;8(3):154-158.
3. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71(3 Suppl): 1098-1109.
4. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3(6): 827-841.
5. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14(6):1756-1764.
6. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17(8):2506-2513.
7. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168(6):2439-2443.
8. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51(18):4845-4852.
9. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57(2):229-233.
10. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79(2):196-202.
11. Budman DR, Calabro A, Kreis W. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002;13(10):1011-1016.
12. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26(5 Suppl 17):14-18.
13. Petrylak DP, Macarthur R, O'Connor J et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 1999;26 (5 Suppl 17):28-33.
14. Petrylak DP, Macarthur RB, O'Connor J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17(3):958-967.
15. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999;10(1):33-38.
16. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
17. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-245.
18. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15): 1513-1520.
19. Kelly WK, Halabi S, Carducci M et al. Randomized, doubleblind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30(13):1534-1540.
20. Tannock IF, Fizazi K, Ivanov S et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013;14(8):760-768.
21. Quinn DI, Tangen CM, Hussain M et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castrationresistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 2013;14(9):893-900.
22. Araujo JC, Mathew P, Armstrong AJ et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012;118(1):63-71.
23. Fizazi KS, Higano CS, Nelson JB et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013;31(14):1740-1747.
24. Scher HI, Jia X, Chi K et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011;29(16):2191-2198.
25. Vrignaud P, Semiond D, Lejeune P et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxaneresistant tumors. Clin Cancer Res 2013;19(11):2973-2983.
26. Bissery MC, Bouchard H, Riou JF et al. Preclinical evaluation of TXD258, a new taxoid. Proceeding of the 91st Annual Meeting of the American Association for Cancer Research. 2000: Abstract 1364.
27. Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res 2012;18(24):6574-6579.
28. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-1154.
29. Bracarda S, Gernone A, Gasparro D et al. Real-world cabazitaxel safety: the Italian early-access program in metastatic castrationresistant prostate cancer. Future Oncol 2013 Dec 3. Epub ahead of print.
30. Basch E, Autio K, Ryan CJ et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patientreported outcome results of a randomised phase 3 trial. Lancet Oncol 2013;14(12):1193-1199.
31. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369(3):213-223.
32. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-422.
33. Kirby BJ, Jodari M, Loftus MS et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PloS One 2012;7(4):e35976.
34. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009;69(14):1579-1585.
35. Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. Urol Oncol 2013;31(8):1457-1463.
36. Pezaro CJ, Omlin AG, Altavilla A et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 2013 Dec 17. Epub ahead of print.